Development and characterization of a new single cycle vaccine vector in the simian immunodeficiency virus model system

Virology

Volumn 372, Issue 1, 2008, Pages 72-84

  Tang, Y ^a   Swanstrom, R ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

HIV 1 vaccine; Lentiviral vector; SIV; VSV G

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; LENTIVIRUS VECTOR; VIF PROTEIN;

ARTICLE; CELL LINE; CONTROLLED STUDY; GENE MUTATION; HEAT SENSITIVITY; HUMAN; IMMUNE SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PSEUDOTYPING; SEROTYPE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

AIDS VACCINES; ANIMALS; CELL LINE; CLONING, MOLECULAR; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; MEMBRANE GLYCOPROTEINS; MUTATION; NEUTRALIZATION TESTS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN IMMUNODEFICIENCY VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 38949195319     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2007.09.023     Document Type: Article

References (67)

1. Aiken C. Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. J. Virol. 71 (1997) 5871-5877
2. Alexander L., Illyinskii P.O., Lang S.M., Means R.E., Lifson J., Mansfield K., and Desrosiers R.C. Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J. Virol. 77 (2003) 6823-6835
3. Baliga C.S., van Maanen M., Chastain M., and Sutton R.E. Vaccination of mice with replication-defective human immunodeficiency virus induces cellular and humoral immunity and protects against vaccinia virus-gag challenge. Mol. Ther. 14 (2006) 432-441
4. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., Krivulka G.R., Beaudry K., Lifton M.A., Gorgone D.A., Montefiori D.C., Lewis M.G., Wolinsky S.M., and Letvin N.L. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415 (2002) 335-339
5. Boge M., Wyss S., Bonifacino J.S., and Thali M. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J. Biol. Chem. 273 (1998) 15773-15778
6. Bosch V., and Pawlita M. Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site. J. Virol. 64 (1990) 2337-2344
7. Bowers K., Pelchen-Matthews A., Honing S., Vance P.J., Creary L., Haggarty B.S., Romano J., Ballensiefen W., Hoxie J.A., and Marsh M. The simian immunodeficiency virus envelope glycoprotein contains multiple signals that regulate its cell surface expression and endocytosis. Traffic 1 (2000) 661-674
8. Cao J., Bergeron L., Helseth E., Thali M., Repke H., and Sodroski J. Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J. Virol. 67 (1993) 2747-2755
9. Chazal N., Singer G., Aiken C., Hammarskjold M.L., and Rekosh D. Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity. J. Virol. 75 (2001) 4014-4018
10. Dal Maso L., and Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol. 4 (2003) 110-119
11. Deacon N.J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D.J., McPhee D.A., Greenway A.L., Ellett A., Chatfield C., Lawson V.A., Crowe S., Maerz A., Sonza S., Learmont J., Sullivan J.S., Cunningham A., Dwyer D., Dowton D., and Mills J. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270 (1995) 988-991
12. DePolo N.J., Harkleroad C.E., Bodner M., Watt A.T., Anderson C.G., Greengard J.S., Murthy K.K., Dubensky Jr. T.W., and Jolly D.J. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J. Virol. 73 (1999) 6708-6714
13. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin. Infect. Dis. 43 (2006) 500-511
14. Edwards T.G., Wyss S., Reeves J.D., Zolla-Pazner S., Hoxie J.A., Doms R.W., and Baribaud F. Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J. Virol. 76 (2002) 2683-2691
15. Evans D.T., Bricker J.E., and Desrosiers R.C. A novel approach for producing lentiviruses that are limited to a single cycle of infection. J. Virol. 78 (2004) 11715-11725
16. Evans D.T., Bricker J.E., Sanford H.B., Lang S., Carville A., Richardson B.A., Piatak Jr. M., Lifson J.D., Mansfield K.G., and Desrosiers R.C. Immunization of macaques with single-cycle simian immunodeficiency virus (SIV) stimulates diverse virus-specific immune responses and reduces viral loads after challenge with SIVmac239. J. Virol. 79 (2005) 7707-7720
17. Fackler O.T., Luo W., Geyer M., Alberts A.S., and Peterlin B.M. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol. Cell 3 (1999) 729-739
18. Fackler O.T., Lu X., Frost J.A., Geyer M., Jiang B., Luo W., Abo A., Alberts A.S., and Peterlin B.M. p21-activated kinase 1 plays a critical role in cellular activation by Nef. Mol. Cell. Biol. 20 (2000) 2619-2627
19. Ferbas J., Daar E.S., Grovit-Ferbas K., Lech W.J., Detels R., Giorgi J.V., and Kaplan A.H. Rapid evolution of human immunodeficiency virus strains with increased replicative capacity during the seronegative window of primary infection. J. Virol. 70 (1996) 7285-7289
20. Frisch M., Biggar R.J., Engels E.A., and Goedert J.J. Association of cancer with AIDS-related immunosuppression in adults. JAMA 285 (2001) 1736-1745
21. Geyer M., Munte C.E., Schorr J., Kellner R., and Kalbitzer H.R. Structure of the anchor-domain of myristoylated and non-myristoylated HIV-1 Nef protein. J. Mol. Biol. 289 (1999) 123-138
22. Geyer M., Fackler O.T., and Peterlin B.M. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2 (2001) 580-585
23. Giebler H.A., Loring J.E., van Orden K., Colgin M.A., Garrus J.E., Escudero K.W., Brauweiler A., and Nyborg J.K. Anchoring of CREB binding protein to the human T-cell leukemia virus type 1 promoter: a molecular mechanism of Tax transactivation. Mol. Cell. Biol. 17 (1997) 5156-5164
24. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., Giangrande P., Luzzi G., Morgan B., Edwards A., McMichael A.J., and Rowland-Jones S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3 (1997) 212-217
25. Grassmann R., Aboud M., and Jeang K.T. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 24 (2005) 5976-5985
26. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., and Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
27. Harris M., and Coates K. Identification of cellular proteins that bind to the human immunodeficiency virus type 1 nef gene product in vitro: a role for myristylation. J. Gen. Virol. 74 (1993) 1581-1589
28. Harris R.S., and Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev., Immunol. 4 (2004) 868-877
29. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., and Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
30. Hirsch V.M., Dapolito G., McGann C., Olmsted R.A., Purcell R.H., and Johnson P.R. Molecular cloning of SIV from sooty mangabey monkeys. J. Med. Primatol. 18 3-4 (1989) 279-285
31. Hirsch V.M., Olmsted R.A., Murphey-Corb M., Purcell R.H., and Johnson P.R. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 339 (1989) 389-392
32. Kamrud K.I., Custer M., Dudek J.M., Owens G., Alterson K.D., Lee J.S., Groebner J.L., and Smith J.F. Alphavirus replicon approach to promoterless analysis of IRES elements. Virology 360 (2007) 376-387
33. Koenig S., Conley A.J., Brewah Y.A., Jones G.M., Leath S., Boots L.J., Davey V., Pantaleo G., Demarest J.F., Carter C., et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1 (1995) 330-336
34. Kuate S., Stahl-Hennig C., ten Haaft P., Heeney J., and Uberla K. Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines. Virology 313 (2003) 653-662
35. Kwok R.P., Laurance M.E., Lundblad J.R., Goldman P.S., Shih H., Connor L.M., Marriott S.J., and Goodman R.H. Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP. Nature 380 (1996) 642-646
36. Lu H., Pise-Masison C.A., Fletcher T.M., Schiltz R.L., Nagaich A.K., Radonovich M., Hager G., Cole P.A., and Brady J.N. Acetylation of nucleosomal histones by p300 facilitates transcription from tax-responsive human T-cell leukemia virus type 1 chromatin template. Mol. Cell. Biol. 22 (2002) 4450-4462
37. Luo T., Douglas J.L., Livingston R.L., and Garcia J.V. Infectivity enhancement by HIV-1 Nef is dependent on the pathway of virus entry: implications for HIV-based gene transfer systems. Virology 241 (1998) 224-233
38. Mack K.D., Jin X., Yu S., Wei R., Kapp L., Green C., Herndier B., Abbey N.W., Elbaggari A., Liu Y., and McGrath M.S. HIV insertions within and proximal to host cell genes are a common finding in tissues containing high levels of HIV DNA and macrophage-associated p24 antigen expression. J. Acquir. Immune Defic. Syndr. 33 (2003) 308-320
39. Mangasarian A., Piguet V., Wang J.K., Chen Y.L., and Trono D. Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J. Virol. 73 (1999) 1964-1973
40. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., and Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003) 99-103
41. Marzio G., Tyagi M., Gutierrez M.I., and Giacca M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13519-13524
42. McCormack M.P., and Rabbitts T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350 (2004) 913-922
43. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., and Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996) 263-267
44. Nusse R., van Ooyen A., Cox D., Fung Y.K., and Varmus H. Mode of proviral activation of a putative mammary oncogene (int-1) on mouse chromosome 15. Nature 307 (1984) 131-136
45. Pan D., Gunther R., Duan W., Wendell S., Kaemmerer W., Kafri T., Verma I.M., and Whitley C.B. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Molec. Ther. 6 (2002) 19-29
46. Pumfery A., Deng L., Maddukuri A., de la Fuente C., Li H., Wade J.D., Lambert P., Kumar A., and Kashanchi F. Chromatin remodeling and modification during HIV-1 Tat-activated transcription. Curr. HIV Res. 1 (2003) 343-362
47. Reiser J., Harmison G., Kluepfel-Stahl S., Brady R.O., Karlsson S., and Schubert M. Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 15266-15271
48. Renkema G.H., Manninen A., Mann D.A., Harris M., and Saksela K. Identification of the Nef-associated kinase as p21-activated kinase 2. Curr. Biol. 9 (1999) 1407-1410
49. Rice A.P., and Herrmann C.H. Regulation of TAK/P-TEFb in CD4+ T lymphocytes and macrophages. Curr. HIV Res. 1 (2003) 395-404
50. Rose N.F., Roberts A., Buonocore L., and Rose J.K. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J. Virol. 74 (2000) 10903-10910
51. Rowell J.F., Stanhope P.E., and Siliciano R.F. Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J. Immunol. 155 (1995) 473-488
52. Saksela K., Cheng G., and Baltimore D. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J. 14 (1995) 484-491
53. Salzwedel K., West J.T., and Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 73 (1999) 2469-2480
54. Sauter M.M., Pelchen-Matthews A., Bron R., Marsh M., LaBranche C.C., Vance P.J., Romano J., Haggarty B.S., Hart T.K., Lee W.M., and Hoxie J.A. An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J. Cell Biol. 132 (1996) 795-811
55. Sawai E.T., Hamza M.S., Ye M., Shaw K.E., and Luciw P.A. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J. Virol. 74 (2000) 2038-2045
56. Schroder A.R., Shinn P., Chen H., Berry C., Ecker J.R., and Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110 (2002) 521-529
57. Sheehy A.M., Gaddis N.C., Choi J.D., and Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002) 646-650
58. Short M.K., Okenquist S.A., and Lenz J. Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats. J. Virol. 61 (1987) 1067-1072
59. Simon J.H., Sheehy A.M., Carpenter E.A., Fouchier R.A., and Malim M.H. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J. Virol. 73 (1999) 2675-2681
60. Spies C.P., and Compans R.W. Effects of cytoplasmic domain length on cell surface expression and syncytium-forming capacity of the simian immunodeficiency virus envelope glycoprotein. Virology 203 (1994) 8-19
61. Swigut T., Iafrate A.J., Muench J., Kirchhoff F., and Skowronski J. Simian and human immunodeficiency virus Nef proteins use different surfaces to downregulate class I major histocompatibility complex antigen expression. J. Virol. 74 (2000) 5691-5701
62. Tung F.Y., Rinaldo Jr. C.R., and Montelaro R.C. Replication-defective HIV as a vaccine candidate. AIDS Res. Hum. Retrovir. 14 (1998) 1247-1252
63. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 (2002) 1896-1905
64. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 (2003) 307-312
65. Wu X., Li Y., Crise B., and Burgess S.M. Transcription start regions in the human genome are favored targets for MLV integration. Science 300 (2003) 1749-1751
66. Wyss S., Berlioz-Torrent C., Boge M., Blot G., Honing S., Benarous R., and Thali M. The highly conserved C-terminal dileucine motif in the cytosolic domain of the human immunodeficiency virus type 1 envelope glycoprotein is critical for its association with the AP-1 clathrin adaptor [correction of adapter]. J. Virol. 75 (2001) 2982-2992
67. Xu X.N., Laffert B., Screaton G.R., Kraft M., Wolf D., Kolanus W., Mongkolsapay J., McMichael A.J., and Baur A.S. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. J. Exp. Med. 189 (1999) 1489-1496